Skip to main content
CM

Corveus Medical

Corveus Medical develops a minimally‑invasive catheter procedure that deactivates a specific sympathetic nerve branch implicated in chronic heart failure progression. By accessing the target nerve through the body’s venous anatomy, the system can ablate and confirm full nerve deactivation during the same procedure, offering physicians a new therapeutic option for moderate heart‑failure patients with limited existing treatments. The approach aims to provide lasting symptom relief and improve outcomes for HFpEF patients.

Houston, TexasFounded 202151K+ followers
Updated 28 days ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Patients with moderate chronic heart failure often experience persistent symptoms despite optimal medical therapy, and there are limited interventional options to halt disease progression.

Solution

Corveus offers a minimally invasive catheter-based procedure that targets and ablates a specific sympathetic nerve branch implicated in heart failure progression. The system navigates through the body's venous anatomy to reach the nerve, and incorporates intra‑procedural monitoring to confirm complete nerve deactivation. By disabling this neural pathway, the therapy aims to reduce symptomatic burden and provide a durable clinical benefit for patients who have exhausted conventional treatments.

Target Audience

Primary customers are interventional cardiologists and heart failure centers seeking an additional therapeutic option for moderate heart failure patients who remain symptomatic despite guideline‑directed medical therapy.

Features

  • Catheter design that leverages native venous routes to access the target sympathetic nerve branch
  • Real‑time electrophysiological feedback to verify full nerve ablation during the procedure
  • Minimally invasive approach reducing procedural risk and recovery time compared to surgical alternatives
  • Integration with standard cardiac catheterization suites for seamless adoption in existing cath labs
  • Evidence‑based rationale supported by recent studies showing benefit of sympathetic denervation in heart failure patients
This profile is AI-generated and may contain inaccuracies.